Car T-Cell Therapy

The FDA granted regenerative medicine advanced therapy designation to CTX110, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory B-cell malignancies.

The FDA granted orphan drug designation to GC012F, a novel chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory multiple myeloma.

Patients with chronic kidney disease are not at an increased risk for AKI or death after chimeric antigen receptor T-cell therapy, according to a speaker at ASN Kidney Week.

In this video, Lori Muffly, MD, MS, discussed a debate session that focused on the sequencing and importance of CD19-targeting therapies from the Society of Hematologic Oncology Annual Meeting.

Results of early clinical trials suggest that chimeric antigen receptor T cells can be adapted successfully to target brain tumors, according to a presenter at AACR Virtual Special Conference: Brain Cancer.

Chimeric antigen receptor T-cell therapy has induced exceptional response rates among patients with relapsed or refractory multiple myeloma compared with conventional options, according to a speaker at Chemotherapy Foundation Symposium.

Significant progress has been made in treatment and improving survival outcomes across all subtypes of acute lymphoblastic leukemia, according to a speaker at Chemotherapy Foundation Symposium.

Chimeric antigen receptor T-cell therapy appeared associated with various cardiovascular and pulmonary adverse events, according to results of a retrospective pharmacovigilance study.

Chimeric antigen receptor T-cell therapy followed by pembrolizumab appeared safe and feasible for patients with malignant pleural mesothelioma, phase 1 trial results published in Cancer Discovery showed.

The FDA has delayed its decision on a biologics license application for ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory multiple myeloma.